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Abstract
Antibodies against type II collagen (CII) are important in the
development of collagen-induced arthritis (CIA) and possibly
also in rheumatoid arthritis. We have determined the fine
specificity and arthritogenicity of the antibody response to CII in
chronic relapsing variants of CIA. Immunization with rat CII in
B10.Q or B10.Q(BALB/c×B10.Q)F2 mice induces a chronic
relapsing CIA. The antibody response to CII was determined by
using triple-helical peptides of the major B cell epitopes. Each
individual mouse had a unique epitope-specific response and
this epitope predominance shifted distinctly during the course of
the disease. In the B10.Q mice the antibodies specific for C1
and U1, and in the B10.Q(BALB/c×B10.Q)F2  mice the
antibodies specific for C1, U1 and J1, correlated with the
development of chronic arthritis. Injection of monoclonal
antibodies against these epitopes induced relapses in chronic
arthritic mice. The development of chronic relapsing arthritis,
initially induced by CII immunization, is associated with an
arthritogenic antibody response to certain CII epitopes.
Introduction
Rheumatoid arthritis (RA) is an autoimmune disorder charac-
terized by a chronic erosive inflammation in joints leading to
the destruction of cartilage and bone. The mechanisms behind
RA are still unclear but early therapy with disease-modifying
drugs such as antibodies against tumor necrosis factor-α  or
methotrexate reduce disease manifestations, and treatment
with anti-CD20 antibodies depleting B cells gives promising
results [1]. The autoimmune targets in RA are not known but
autoantibodies against various joint-related epitopes are
detected in sera. Antibodies against epitopes modified by cit-
rullination show the highest specificity for RA and can be
detected very early in the disease course [2-4]. Antibodies
against type II collagen (CII) occur in a subset of RA, and CII-
specific B and T-cells have been identified in rheumatoid syn-
ovium and synovial fluid [5-10].
Immunization of mice with CII leads to the development of
arthritis, the collagen-induced arthritis (CIA) model for RA. CII-
specific activation of both T and B cells is critical for the devel-
opment of arthritis, and the transfer of both rodent [11] and
human [12] serum with CII-specific antibodies induces arthri-
tis in mice. Monoclonal CII-specific autoantibodies bind carti-
lage in vivo and induce arthritis [13]; the injection of large
amounts of several of such mAbs in cocktails induces severe
arthritis [14,15]. Collagen-antibody-induced arthritis (CAIA) is
an inflammation that is dependent on Fc receptor and comple-
ment, involving the infiltration of both neutrophils and macro-
phages [15-18].
The antibody response to CII is predominantly directed
towards the conformational triple-helical structures. Immuniza-
tion with CII α -chains (denatured CII) induces only a weak anti-
body response and is not arthritogenic [19]. Therefore
identification of the relevant B cell epitopes required the con-
struction of recombinant triple-helical proteins and synthetic
triple-helical peptides [10,20]. The major epitopes were iden-
tified with the use of series of mAbs from both mice and rats
CFA = complete Freund's adjuvant; CIA = collagen-induced arthritis; CII = type II collagen; DMEM = Dulbecco's modified Eagle's medium; ELISA = 
enzyme-linked immunosorbent assay; i.d. = intradermally; IFA = incomplete Freund's adjuvant; mAb = monoclonal antibody; PBS = phosphate-buff-
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[13,20-22]. Interestingly, antibodies against some of the major
epitopes (C1 and J1) are arthritogenic, whereas antibodies
against others (F4) are not [10]. The immunodominance of
these epitopes seems to be shared between both CIA in mice
and rats and in humans with RA [10,20,22,23].
Until now, CIA has mainly been studied as an acute disease.
Because RA is chronic progressive and shows relapsing
inflammatory destruction of cartilage, we wished to investigate
the antibody response and B cell epitope specificity in chronic
CIA models; that is, with an active joint inflammation later than
6 weeks after the onset. The advantages of following the anti-
body response over a longer period are that we can find pos-
sible associations between epitope specificities and the
different phases of the disease and can also find epitope shifts
during the course of the disease. We have observed previ-
ously that mice with C57Bl/10 backgrounds tend to get more
chronic arthritis although they are initially relatively more resist-
ant than DBA/1 mice, for example [24]. We therefore immu-
nized B10.Q mice, which have an arthritis-susceptible Aq
class II congenic fragment on the C57B1/10 background,
with rat CII, and found that they develop a chronic relapsing
disease. We have also recently defined another strain combi-
nation, an F2 cross between B10.Q and BALB/c, that give an
even more pronounced development of chronic arthritis. It
could be shown that the changes in epitope specificity occur
during the course of the disease. Interestingly, the C1, U1 and
J1 epitope-specific antibodies were associated with the devel-
opment of severe and chronic arthritis. Single injections of




All animals were bred and kept in a climate-controlled environ-
ment (temperature and humidity) with cycles of 12 hours light/
12 hours dark at the animal facility of Medical Inflammation
Research, Lund University. Male B10.Q mice and
B10.Q(BALB/c×B10.Q)F2 mice of both sexes (8 to 12 weeks
old) were used for the CIA experiments. B10.Q(BALB/
c×B10.Q)F2 mice (45 to 49 weeks old) were used for the
induction of relapse experiment. Local animal welfare authori-
ties permitted all the animal experiments.
Induction and evaluation of CIA
B10.Q mice (n = 25) were immunized intradermally (i.d.) at the
base of the tail with 100 µg of rat CII in 0.1 M acetic acid,
emulsified in complete Freund's adjuvant (CFA; Difco, Detroit,
IL, USA) [25]. They were boosted subcutaneously on day 35
with 50 µg of CII in incomplete Freund's adjuvant (IFA; Difco,
Detroit, IL, USA). Control mice (n = 5) were immunized with
0.1 M acetic acid emulsified in CFA and boosted on day 35
with 0.1 M acetic acid in IFA. Clinical scoring was performed
for 156 days as described previously [25]; in brief, each
inflamed toe or knuckle scores one point, whereas an inflamed
wrist or ankle scores five points, resulting in a maximum score
of 15 (five toes plus five knuckles plus one wrist/ankle) for
each paw and 60 points for each mouse. The mice were
scored twice or three times a week, except during the first 25
days when they were scored once a week. Serial eye bleeding
was performed over a period of 156 days, three times a week
during the first 5 weeks and then twice a week for the remain-
ing time. To perform retro-orbital bleeding, capillary tubes (75
mm KEBO-Lab) were used and 30 µl of sera were collected
at each bleeding time point.
B10.Q(BALB/c×B10.Q)F2 mice were immunized with 100 µg
of rat CII emulsified in IFA administered i.d. at the base of the
tail on day 0 and boosted i.d. on day 35 with 50 µg of rat CII
in IFA. The mice were scored for a minimum period of 207
days for arthritis development, with the same scoring protocol
as described above.
Triple-helical peptides
The triple-helical peptides were synthesized essentially as
described by Grab and colleagues [26]. The strategy for syn-
thesis was as a first step to produce the peptide NH2-Lys-Lys-
Tyr(tBu)-Gly-resin, creating a handle with three amino groups
used for synthesis of the strands of the triple helix in parallel
and creating a covalent link between all three strands at the
carboxy terminus. The procedure of Grab and colleagues [26]
was used with the following modifications. All synthesis was
performed in an ABI 431 peptide synthesizer (Foster City, CA,
USA) operated with the FastMoc procedure. The synthesis
was performed with a capping procedure, minimizing the pres-
ence of peptide material lacking amino acids within the
sequence. The resin used for synthesis was a Fmoc-glycine-
Wang resin. All Fmoc (fluoren-9-ylmethoxycarbonyl) amino
acid derivatives were used as single amino acids. The removal
of the temporary lysine side chain protection ivDde [1-(4,4-
dimethyl-2,6-dioxo-cyclohexylidene)3-methyl-butyl] was per-
formed by treatment of the peptide resin with 2% hydrazine in
N,N-dimethylformamide for 3 min; the procedure was
repeated three times. The peptide resin was washed with N,N-
dimethylformamide after treatment with hydrazine.
After completion of the synthesis the peptide was removed
from the resin and all side chain protection groups were
removed by treatment with a cleavage cocktail containing 5%
phenol, 2% 1,2-ethanedithiol, 5% methyl phenyl sulfide, 5%
water and 84% trifluoroacetic acid. The peptide resin was
treated for 2 hours at 22°C, after which the resin was filtered
off and the peptides were precipitated and washed with die-
thyl ether. Peptides were used without further purification. A
control of the synthetic peptides was obtained by the analysis
of tryptic fragments by MALDI-TOF (matrix-assisted laser des-
orption ionization-time-of-flight) mass spectrometry (Kompakt
IV instrument; Kratos, Manchester, UK.) Chemicals were of
analytical or synthetic grade, amino acid derivatives were
obtained from Alexis Biochemicals (Lausen, Switzerland), andAvailable online http://arthritis-research.com/content/7/5/R1148
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Fmoc-Lys(ivDde)-OH and Wang resin were from Novabio-
chem (Laufelfingen, Switzerland).
ELISA
Microtiter plates (Corning Costar Corp., Cambridge, MA,
USA) were coated overnight with either CII (10 µg/ml in PBS),
or with one of the CII-specific epitopes C1, T1, J1 or U1 at 4
µg/ml concentration in PBS at 4°C and blocked with 1%
bovine serum albumin (Sigma) in PBS for 1 hour at room tem-
perature. The CII-specific response or the epitope specificities
were determined by adding the sera at a standard dilution of
1:100 in PBS to the various CII-coated or epitope-coated
plates for 2 hours at room temperature. Antibody binding was
detected with horseradish peroxidase-conjugated goat anti-
mouse total IgG (Jackson ImmunoResearch  Laboratories,
West Grove, PA, USA) and 2,2-azino-di-(3-ethylbenzthiazoline
sulfonate) diammonium salt as substrate (ABTS tablets; Boe-
hringer-Mannheim, Germany). The absorbance value was
determined at 405 nm in duplicates. To determine the concen-
tration of specific antibodies, we used a positive DBA/1 stand-
ard sera (titrated 0.5 to 10 µg/ml) and the computer program
SOFTmaxPRO version 2.6.1. As standards for the epitope-
specific ELISAs we used the mAbs listed in Table 1. In a sim-
ilar manner to the polyclonal standard we calculated the
amount of antibodies. However, because the monoclonal
standards differ in affinity, the values are not comparable to
each other and are therefore transformed to arbitrary units
(AU). One AU is 1 µg/ml as calculated with a mAb standard.
Normal B10.Q or B10.Q(BALB/c×B10.Q)F2  mouse sera
were included in all assays and this absorbance value (0.1)
determined the cut-off value.
B cell hybridomas producing mAbs
The CIIC1, M2139 and 122.9 hybridomas have been
described previously [13,21,22]. The UL1 hybridoma was
established by immunizing a B10.Q mouse with 100 µg of rat
CII emulsified in CFA. The mouse was first boosted subcuta-
neously at day 35 with 50 µg of rat CII in IFA. Five days before
the fusion (day 210), the mouse was boosted a second time
with 50 µg of triple-helical peptide containing the U1 epitope,
in IFA, in the footpad. Draining lymph node cells were isolated
and fused with myeloma (NSO) cells, and the subsequent
cloning and anti-CII antibody selection were performed essen-
tially as described previously [27]. For the production of anti-
bodies the hybridomas were expanded in DMEM Glutamax-1
medium containing 0.5% streptomycin and 0.6% penicillin
and Ultra low IgG fetal bovine serum (FBS) (Gibco BRL,
Grand Island, NY, USA). The mAbs were purified from culture
supernatants by affinity chromatography on protein G (Gam-
maBind plus Sepharose; Pharmacia, Uppsala, Sweden) and
all solutions for affinity chromatography were prepared in
accordance with the GammaBind Sepharose manual. The
mAbs were dialyzed against PBS. The concentrations of the
mAbs were determined by freeze-drying. The solutions with
antibodies were filter-sterilized with 0.2 µm syringe filters
(Dynaagard, Spectrum Laboratories, CA) and stored at -70°C
until used.
Induction of relapses with mAbs in chronic mice
The B10.Q(BALB/c×B10.Q)F2 mice were immunized with
100 µg of rat CII emulsified in IFA i.d. at the base of the tail on
day 0 and boosted on day 35 i.d. with 50 µg of rat CII in IFA.
The mice were scored for a minimum period of 207 days for
arthritis development. Mice that developed chronic arthritis
(mice with severe arthritis for a minimum period of 120 days
were considered to be chronic) were selected for this experi-
ment. Clinical scoring was performed as described previously
[25]. Groups of chronic mice (n = 6) were injected intrave-
nously with a single mAb, 9 mg of either CIIC1, M2139 or UL1.
Development of clinical arthritis was followed through daily vis-
ual scoring of the mice, starting the day after the antibody
transfer and continuing until the end of the experiment. Arthritis
was evaluated as described above.
Statistical analysis
The Statview software program was used for the statistical
analysis. The Mann-Whitney U (MW) test was applied to eval-
uate comparisons of antibody titres and scoring. The Pearson
correlation coefficient, r, was calculated between the mean
arthritis score and the logarithmic antibody response at
Table 1
Epitope sequences and epitope specificities of mAbs
Epitope Epitope sequence (epitope in THP)a MAbs Antigen reactivityb
Clone Isotype CII C1 J1 T1 U1
C1 GPBGPBGPBGPBGPBG-ARGLTGRBGDA-GPBGPBG-ε ACA CIIC1 IgG2a 1.7 2.5 0.0 0.0 0.0
J1 GPBGPBGPBGPBGPBG-MBGERGAAGIAGPK-GPBGPBG-ε ACA M2139 IgG2b 2.4 0.0 2.5 0.0 0.0
T1 GPBGPBGPBGPBGPBG-IAGFKGEQGPKGEP-GPBGPBG-ε ACA 122.9 IgG2a 1.7 0.0 0.0 2.5 0.0
U1 GPBGPBGPBGPBGPBG-LVGPRGERGFB-GPBGPBG-ε ACA UL1 IgG2b 2.1 0.0 0.0 0.0 2.4
aAll epitopes were in native triple-helical form. Amino acids are abbreviated as follows: G, glycine; P, proline; B, hydroxyproline; E, glutamic acid; 
R, arginine; K, lysine; H, histidine; F, phenylalanine; A, alanine; L, leucine; T, threonine; Y, tyrosine; ε ACA, ε -aminohexanoic acid-lysine-lysine-
tyrosine-glycine-OH. bAbsorbance at 405 nm in ELISA tested with affinity-purified mAbs. In the ELISA plates, all the triple-helical peptides were 
coated at 4 µg/ml, whereas type II collagen (CII) was coated at 10 µg/ml. CIIC1, M2139 and UL1 are mouse monoclonal antibodies and were all 
tested at a concentration of 1 µg/ml; 122.9 is a rat monoclonal antibody and was tested with culture supernatant.Arthritis Research & Therapy    Vol 7 No 5    Bajtner et al.
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specific time points. The r value measures the degree of rela-
tionship between two variables and varies between 0 and 1,
where high r indicates a strong linear relationship. P < 0.05
was considered significant in all analyses.
Results
Chronic arthritis in B10.Q mice
To investigate the epitope specificity of B cells in sera from
arthritic mice, we immunized male B10.Q mice (n = 25) to
induce CIA. The mice started to develop arthritis on day 25
and reached an incidence of 60% (Fig. 1a). The disease
course could be divided into two phases, acute (from days 0
to 70) and chronic (from days 74 to 156), because there was
a decrease in the mean arthritis score on day 70 after immuni-
zation; that is, about 6 weeks after onset. Between these two
phases there was a recovering period, during which the mean
score value decreased. In the later phase, the paws were
destroyed but clear relapses of arthritis could be detected in
specific joints and during limited times, most clearly seen
when the arthritis disease course is depicted for individual
mice (Fig. 1b, mice 6, 7, 13, 14 and 15). We therefore defined
the durations of the acute and chronic phases of the disease
as above.
The anti-CII response to specific epitopes in individual 
mice is immunodominant but shift during the disease 
course
For a specific screening of the sera against the major epitopes,
we synthesized triple-helical peptides, covalently linked at the
C terminus and with several glycine-proline-hydroxyproline tri-
plets at the N terminus. The specificities of the peptides were
shown by using mAbs for the various epitopes (Table 1). Anal-
ysis of the results of the individual sera clearly shows that each
mouse had its own immunodominance pattern; that is, it
responded mainly to one or a few epitopes. In addition, this
response often sharply shifted during the course of the dis-
ease, possibly reflecting a clonal origin of this epitope spread-
ing of the antibody response, see for example mouse 6 (Fig.
1b).
To be able to investigate the results from the anti-CII response
to specific epitopes in individual mice and compare with the
scoring during the same time period, we analyzed each paw in
individual mice and found clear relapses of the disease (Fig.
1b). An example is mouse 7, in which the C1-specific antibod-
ies dominated before arthritis, whereas U1 antibodies domi-
nated during both the active acute phase and the active
chronic phase of arthritis (Fig. 1b). In mouse 13, again the anti-
bodies specific for U1 and C1 were immunodominant, but the
U1 antibodies showed a very high response in the chronic
phase and this correlated very well with the scoring curve for
mouse 13 (Fig. 1b). In mouse 14, U1 antibodies dominated
during both the active acute phase and the active chronic
phase of arthritis, with very high antibody responses during the
disease course (Fig. 1b). In mouse 15, the U1-specific anti-
bodies dominated during the whole disease course (Fig. 1b).
We could detect the C1-specific antibodies early on day 11
before we could see any clinical signs in this mouse. These
antibodies dominated in the active acute phase of arthritis and
then decreased.
These individual patterns of antibody responses indicate a
strong environmental or stochastic factor in the selection of
the antibody response to specific CII epitopes. However, links
to the development of chronic relapsing arthritis are also
indicated.
The total anti-CII response
Antibodies against CII were detected from day 11 and
showed a sharp increase during the following days, but arthri-
tis developed several weeks later (Fig. 2a). To investigate
which role the CII-specific antibodies might have in the induc-
tion and perpetuation of arthritis during the course of the dis-
ease, we calculated correlations between arthritic scores and
anti-CII antibody levels (Fig. 2b). Here we show that the corre-
lation, r, between the arthritic score and anti-CII antibody lev-
els increased with time and again confirm that animals
developing arthritis had significant levels of anti-CII antibodies.
To investigate whether the levels of anti-CII antibodies were
more critical at the onset of the disease we compared the total
anti-CII serum levels at 3 days before the onset day of each
animal that developed disease with the levels in those that
remained healthy; we found a more pronounced difference (P
= 0.0002). Still, the total anti-CII antibody levels were polyclo-
nal; to address whether epitope specificity might have a role
we investigated the response against the major CII epitopes
(denoted C1, J1, U1 and T1).
Antibody responses against triple-helical peptides 
correlate with the late phase of arthritis
The antibody responses against the triple-helical peptides
were measured by ELISA; we found that the mean antibody
response against the triple-helical peptides varied. However,
the antibody responses against C1 and U1 showed increased
levels of antibodies as early as day 11 (Fig. 3a, c), whereas the
levels of antibodies against J1 and T1 gradually increased to
reach a maximal level at the onset of arthritis (data not shown).
To investigate the possible role of the antibodies specific for
C1 and U1 in arthritis during the course of the disease, we cal-
culated correlations between arthritis scores and anti-epitope
antibody levels (Fig. 3b, d). Here we show that the correlation,
r, between the arthritic score and the anti-U1 antibody level is
higher, with significant values of r for longer periods at differ-
ent time points during the course of the disease than the cor-
relation between the arthritic score and anti-C1 antibody level.
To investigate these findings in another chronic arthritis mouse
model, we analysed sera from a CIA experiment in
B10.Q(BALB/c×B10.Q)F2 mice in the same way.Available online http://arthritis-research.com/content/7/5/R1148
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Figure 1
Arthritis development in B10.Q mice and antibody response to CII-specific epitopes in individual mice Arthritis development in B10.Q mice and antibody response to CII-specific epitopes in individual mice. (a) Arthritis course during 156 days of male 
B10.Q mice 8 to 12 weeks old (n = 25) immunized with CII in complete Freund's adjuvant on day 0 and boosted on day 35 with CII in incomplete 
Freund's adjuvant, showing the arthritis score of the diseased (n = 15, open squares) and healthy (n = 10, open circles) mice. The disease course is 
divided into an acute phase (days 0 to 70) and a chronic phase (days 74 to 156). The incidence was 60%. Results are means ± SEM. (b) Antibody 
response to specific CII epitopes and arthritis development in individual B10.Q mice. The epitope specificity in mouse 6 during the course of the dis-
ease shows the immunodominance of antibodies against the epitopes U1, C1 and J1. Arthritis disease course in mouse 6 indicates the score of the 
individual paws. LH is the left hind paw, RH is the right hind paw, LF is the left front paw and RF is the right front paw. The epitope specificity in 
mouse 7 during the course of the disease shows the immunodominance of antibodies against the epitopes U1 and C1. The disease course in 
mouse 7 indicates the score of the individual paws during the disease course. The epitope specificity in mouse 13 during the course of the disease 
shows the immunodominance of U1-specific antibodies. The disease course correlates with the U1 antibody response in mouse 13. The epitope 
specificity in mice 14 and 15 during the course of the disease shows the immunodominance of antibodies against the epitope U1. Antibodies 
against the C1 epitope were detectable in mouse 14 and were detectable before the onset of the disease and also during the acute phase of arthri-
tis in mouse 15. The disease course in mice 14 and 15 indicates the score of the individual paws during the disease course.Arthritis Research & Therapy    Vol 7 No 5    Bajtner et al.
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B cell epitope specificity in a chronic relapsing arthritis 
model
To study the B cell epitope specificity in sera from another
chronic arthritis model in mice, we investigated sera from
B10.Q (BALB/c×B10.Q)F2 mice (n = 190) immunized for the
induction of CIA. The mice were scored for a minimum of 210
days for arthritis development. About 4 weeks (on day 31)
after the immunization, the mice started to develop a chronic
relapsing disease (Fig. 4a). The incidence was 51%. The mice
were bled on days 35, 80 and 210. We found a correlation
between antibodies against CII, C1, J1 and U1 and the
arthritic score on days 35, 80 and 210 (Fig. 4b). Although the
values of r were low for CII and all the epitopes screened on
day 35, they were significant. Because these mice showed a
chronic relapsing disease, we further investigated the epitope
specificity around the relapses.
CII epitope-specific responses differ during different 
phases of arthritis progression
We analyzed sera taken on days 80 and 210 from mice that
showed a relapse at about day 80 (ranging from days 75 to
85; n = 32) or at about day 210 (ranging from days 200 to
210; n = 21) for their epitope specificity. To investigate the
role of the epitope-specific antibodies for the induction of the
relapse, we made correlation studies between arthritic score
and antibody level. Regression analysis showed a significant
correlation between arthritic score and the antibody response
against J1 epitope on day 80 and a significant correlation
between arthritic score and the antibody response against C1
epitope on day 210 (Fig. 4c).
Single anti-CII antibody induces relapses
We wished to study whether a single anti-CII antibody is capa-
ble of inducing a relapse in mice with chronic arthritis. For this
experiment we chose the chronic relapsing variant of CIA that
develops in mice with mixed B10 and BALB/c backgrounds.
B10.Q × (BALB/c×B10.Q)F2 mice were immunized with CII in
IFA on days 0 and 35 and evaluated for arthritis for 210 days.
These mice are genetically heterogeneous and only mice with
severe and active chronic relapsing arthritis for a minimum of
120 days were selected for the experiment. The single injec-
tion of the antibodies CIIC1, M2139 and UL1 was performed
on day 265 in these mice. Before antibody injection most of
the mice had active arthritis (mean maximum score 8.1 ± 2.0).
The basal level score from day 265 was subtracted from the
observed arthritis score values in individual mice; 17% of
these mice were relapsing on day 265. We injected 9 mg of
single mAbs (CIIC1, M2139 or UL1). After injection, 80 to
100% of these mice were relapsing within 2 days (Fig. 5).
Discussion
To study the role of a specific and arthritogenic B cell
response to cartilage during a chronic relapsing arthritis
Figure 2
Development of antibody response to CII and correlation between  arthritis severity and anti-CII response Development of antibody response to CII and correlation between 
arthritis severity and anti-CII response. (a) Mean antibody responses 
measured in sera against CII over time in control (open circles, n = 5), 
healthy (open triangles, n = 10) and arthritic (open squares, n = 15) 
mice. (b) Analysis of the correlation between the mean arthritis score 
and the anti-CII response during the disease course. Each point repre-
sents the correlation coefficient, r. The values of r are significant from 
day 85 to day 156.
Figure 3
Antibody response to C1 and U1 and correlations between arthritis  severity and anti-epitope response Antibody response to C1 and U1 and correlations between arthritis 
severity and anti-epitope response. (a) Mean antibody responses 
measured in sera against the C1 triple-helical peptide over time in con-
trol (open circles, n = 5), healthy (open triangles, n = 10) and arthritic 
(open squares, n = 15) mice. (b) Analysis of the correlation between 
the mean arthritis score and the anti-C1 response during the disease 
course. Each point represents the correlation coefficient, r. The values 
of r are significant on days 37, 42, 78, 92, 106 to 113 and 120 to 156 
and range from P ≤  0.05 to P ≤  0.0001. (c) Mean antibody responses 
measured in sera against the U1 triple-helical peptide over time in con-
trol (open circles, n = 5), healthy (open triangles, n = 10) and arthritic 
(open squares, n = 15) mice. (d) Analysis of the correlation between 
the mean arthritis score and the anti-U1 response during the disease 
course. Each point represents the correlation coefficient, r. The values 
of r are significant on days 32 to 92, 99 to 113 and 120 to 156.Available online http://arthritis-research.com/content/7/5/R1148
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disease course, we studied unique models of chronic relaps-
ing CIA in mice. The development of chronic arthritis is related
to an antibody response to defined epitopes on CII. Interest-
ingly, the antibodies directed against distinct epitopes on the
triple-helical part of CII correlate with chronic arthritis and
induce arthritis relapses.
In the CIA model, the triggering of autoreactive B cells to CII
is undoubtedly an important pathogenic factor during the
acute phase of the disease. B cell-deficient mice are com-
pletely resistant to CIA [28] and the arthritis can be passively
transferred with immune sera [11] and also induced with
mAbs against CII [13-15]. However, the development of arthri-
tis has not been perfectly correlated with serum titers of anti-
bodies against CII because high titers of antibodies do not
always lead to severe arthritis [29]. This is also observed in
inbred strains, also suggesting other than genetic explana-
tions. Thus, immunization of inbred mouse strains susceptible
to CIA induces a variable titer of antibodies. In the present
investigation evidence is presented for both a genetic and a
non-genetic influence on the autoantibody specificity to CII.
The analysis of chronic arthritis in B10.Q mice shows that indi-
vidual but genetically identical mice varied markedly in specif-
icity. However, mean values showed that the antibody
Figure 4
Arthritis development in B10.Q(BALB/c×B10.Q)F2 mice and correla- tions between relapsing arthritis and responses to CII/CII-specific  epitopes Arthritis development in B10.Q(BALB/c×B10.Q)F2 mice and correla-
tions between relapsing arthritis and responses to CII/CII-specific 
epitopes. (a) Arthritis course during 207 days of male and female 
B10.Q(BALB/c×B10.Q)F2 mice (8 to 12 weeks old) immunized with 
100 µg of rat CII emulsified in incomplete Freund's adjuvant (IFA) on 
day 0 and boosted on day 35 with 50 µg of rat CII in IFA, showing the 
arthritis score of the diseased (n = 96, open squares) and healthy (n = 
94, open circles) mice. Arrows indicate the bleeding time-points (days 
35, 80 and 210). Results are means ± SEM. (b) Analysis of the correla-
tion between the mean arthritis score and the anti-CII or anti-epitope 
responses during the disease course. Each point represents the corre-
lation coefficient, r. The values of r are significant on day 35, 80 and 
210 for CII, C1, J1 and U1. (c) Analysis of the correlation between the 
mean arthritis score and the anti-CII or anti-epitope responses related 
to mice with a relapsing disease, either on day 80 (n = 32) or on day 
210 (n = 21). Each bar represents the correlation coefficient, r. The val-
ues of r are significant for the J1 epitope on day 80 and for the C1 
epitope on day 210.
Figure 5
A single anti-CII antibody induces relapses A single anti-CII antibody induces relapses. Induction of relapses in 
chronic mice (n = 6) injected with a single mAb, namely 9 mg of CIIC1 
(open circles), M2139 (open squares) or UL1 (filled triangles). The inci-
dence in the groups of mice injected with CIIC1 and M2139 was 
100% and the incidence in the group of mice injected with UL1 was 
83%. The selected chronic B10.Q (BALB/c×B10.Q)F2 mice had previ-
ously been immunized with 100 µg of rat CII in incomplete Freund's 
adjuvant (IFA) on day 0 and boosted on day 35 with 50 µg of rat CII in 
IFA. Mice that developed chronic arthritis (mice with severe arthritis for 
a minimum period of 120 days were considered to have chronic arthri-
tis) were selected for the induction of relapses. Antibodies were 
injected on day 265 in these mice. Most of the mice had active arthritis 
before antibody injection (mean maximum score 8.1 ± 2.0). The basal 
level score from day 265 was subtracted from the observed arthritis 
score values in individual mice; 17% of these mice were relapsing on 
day 265. The basal levels of CII epitope-specific antibodies in sera just 
before injection of anti-CII antibodies are as follows: RCII, 95 µg/ml; 
C1, 15 AU; J1, 70 AU; and U1, 15 AU. Results are means ± SEM. AU, 
arbitrary units.Arthritis Research & Therapy    Vol 7 No 5    Bajtner et al.
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response to mainly U1 and C1 were associated with the devel-
opments of chronic arthritis. The comparison with the geneti-
cally segregating F2 mice, in which BALB/c genes had been
introduced showed that the individual variety led to a strong
association to all of the investigated CII epitopes, the C1, U1
and J1 epitopes.
Chronic development of CIA has not previously been exten-
sively investigated. In both the present study and one pub-
lished previously [24] the C57Bl/10 background was used. In
two of these experiments the involvement of C3H and BALB/
c genes apparently promoted the development of chronicity.
The development of chronic arthritis in the B10.Q strain was
more pronounced than we normally observed; we assume that
the boosting effect of repetitive bleeding could have enhanced
the relapsing pattern.
The development of a unique epitope-specific antibody
response shifting along the chronic disease course in each
individual mouse is not only genetically controlled but also a
stochastic process. An explanation could be that the selection
of which B cell will form the germinal centers occurs as a
response to CII derived from cartilage and that this selection
is more or less random. The B cell response to CII is a strictly
T cell-dependent process engaging germinal-center B cells
that predominantly switch isotype to IgG and that to a large
extent are somatically mutated [30,31]. Thus, for the new prim-
ing events to occur it is likely that both T and B cells specific
for cartilage-derived CII are involved. Clearly, the specificity of
the antibody response is changed during the development of
chronic arthritis, indicating that the recognition of the CII used
for immunization is different from that of CII derived endog-
enously from cartilage.
In the present experiments, in which we used only mice
expressing the MHC class II molecule Aq, it is likely that the
same B and T cell epitopes are recognized. A difference could
be that the affinity for the T cell-recognized peptide in rat CII,
used for immunization, is higher than in mouse CII [32]. Other
contributing reasons could be that CII is exposed differently
when scavenged from cartilage compared with when it is
exposed in the immune inocula in the skin. The quality of the
endogenous priming of the immune system is also likely to be
different because neo-epitopes on CII in cartilage are formed
by a changed glycosylation pattern [33,34] but also by proc-
esses modified by the inflammatory process itself, such as
citrullination and oxidation [3,35,36]. The major epitopes on
triple-helical CII, including C1, J1 and U1, seem to share a
common motif, consisting of arginine-glycine-hydrophobic
amino acid, which is possibly also located in a repetitive way
on the cartilage surface or in CII aggregates, known to occur
in an inflamed synovium [20,37,38].
As regards the consequence of the recognition of the
changed epitope by antibodies we have now shown that anti-
bodies against each of the major B cell epitopes on CII induce
a relapse of arthritis in chronic arthritic mice. In most earlier
studies the induction of collagen-antibody-induced arthritis
requires both several anti-CII antibodies and a boosting injec-
tion of lipopolysaccharide [14,15,39]. As this was not neces-
sary for inducing a relapse in chronic arthritic mice it is likely
that the threshold for developing antibody-mediated arthritis in
these mice is lower, possibly because they already have an
ongoing anti-CII immunity. Nevertheless, it clearly shows that
a sudden increase in antibody response to a single CII
epitope, as we have noted to occur spontaneously during the
course of the disease, is capable of inducing severe arthritis.
The question arises whether this phenomena is unique to the
mouse, whether we can use the mouse as a model to study the
process in principle or whether in fact the same epitopes are
engaged in other species, including humans. Interestingly, the
data accumulated so far indicate that the epitope specificity of
the response is shared between species. The major epitopes
dominating so far are predominantly seen in mice and rats with
CIA as well as in humans with RA [10,20,22,23]. Interestingly,
antibodies against both the C1 and the U1 epitopes are posi-
tively correlated with RA, whereas the response to epitopes
recognized by arthritis-protective antibodies recognizing the
F4 epitope is not [10]. Even though RA is not primed by a CII
immunization as in mice and rats, adaptive immunity to CII
does occur in some patients, possibly because of exposure to
modified CII from cartilage [40]. This could have a role in main-
taining chronic inflammation in some cases of RA.
Conclusion
We demonstrated that antibodies directed to distinct epitopes
on the triple-helical part of CII are correlated with chronic
arthritis and are arthritogenic in the mouse CIA model. We
could show that each mouse develops a unique epitope-spe-
cific antibody response that may shift and spread to other
epitopes during the course of the disease, indicating that new
priming events occur. Clearly, the specificity of the antibody
response is changed during the development of chronic arthri-
tis, in particular engaging the major epitopes C1, U1 and J1.
Injection of mAbs against these epitopes induces relapses in
chronic arthritic mice. Thus, the development of chronic
relapsing arthritis in mice, initially induced by CII immunization,
is associated with an arthritogenic antibody response to cer-
tain CII epitopes.
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